MedPath

ow-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastastic pancreatic cancer: A randomized phase II trial

Not Applicable
Conditions
Metastatic pancreatic cancer
Registration Number
JPRN-UMIN000024505
Lead Sponsor
Kindai University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1)Pulmonary fibrosis/pneumonia interstitialis 2)Serous diarrhea 3)Active infection 4)Serious complication 5)modelate or severe pleural effusion/ascites 6)Brain metastasis with sympsons 7)Active multiple primary cancer 8)Use of warfarin potassium 9)During pregnancy 10)Serious mental disorders 11)The other inappropriate case

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath